Table 1.
Sample sociodemographic and medical characteristics
| Sociodemographics | |
| Female | 87.97% (117/133) |
| Age | M=56.21 (SD=11.59); Md=58.00 Range=21–75 |
| Race/Ethnicity | White/Caucasian & Not Latino/a: 84.21% (112/133) Hispanic/Latino/a: 9.77% (13/133) Biracial: 2.26% (3/133) Other: 1.50% (2/133) Asian American: 1.50% (2/133) Black/African American:.75% (1/133) |
| Education (median) | Bachelor’s degree |
| Household income (median) | $61,000-$80,000 |
| Married or partnered | 68.42% (91/133) |
| Cancer treatment history | |
| Months between end of active cancer treatment and study enrollment | M=8.70 (SD=6.33) |
| % of each who received: 1) Surgery 2) Chemotherapy 3) Radiation |
1) 77.44% (103/133) 2) 68.42% (91/133) 3) 55.64% (74/133) |
| Cancer type | |
| Breast | 59.40% (79/133) |
| Lymphoma | 10.53% (14/133) |
| Gastrointestinal | 9.02% (12/133) |
| Gynecologic | 4.51% (6/133) |
| Lung | 3.76% (5/133) |
| Prostate or testicular | 3.01% (4/133) |
| Head and neck | 3.76% (5/133) |
| Multiple myeloma | 3.01% (4/133) |
| Other | 3.01% (4/133) |
| Cancer stage (solid tumor cancers only) | |
| 0 | 2.63% (3/114) |
| I | 36.84% (42/114) |
| II | 29.82% (32/114) |
| III | 25.44% (29/114) |
| IV | 5.26% (6/114) |
| Current medication use1 | |
| % on psychiatric medication | 44.26% (54/122) |
| % on sleep medication | FDA-regulated=26.23% (32/122) Alternative (herbal)=14.75% (18/122) |
| % on pain medication | 33.61% (41/122) |
| % on anti-hormonal medication (includes ovarian suppression medication) | 40.98% (50/122) |
| % on maintenance chemotherapy or immunotherapy | 9.02% (11/122) |
1
Data are unavailable for 11 participants, as we did not initially assess medication use.